-
ALSO READ
Regeneron antibody cocktail helps prevent symptomatic Covid-19: Drugmaker
Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib
BDR Pharma inks licensing pact with Eli Lilly for Covid-19 treatment drug
Lilly hit by staff accusations, FDA scrutiny at Covid-19 drug factories
Roche's Covid antibody cocktail available at Indraprastha Apollo Hospitals
-
Eli Lilly and Company India on Tuesday said it has received permission for emergency use of its antibody drugs combination used for treatment of mild to moderate Covid-19, in the country.
The company has received permission for restricted emergency use of its monoclonal antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, used together for the treatment of patients with mild to moderate Covid-19, Eli Lilly said in a statement.
"Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab in order to speed up access and provide treatment options for patients with Covid-19," it added.
Bamlanivimab and etesevimab combination has been authorised under Emergency Use Authorisation in the US and select EU countries for the treatment of the disease, the statement said.
"We are pleased that we have another innovative treatment option to offer India's healthcare providers who continue to be at the forefront of the battle against Covid-19," Eli Lilly and Company India MD Luca Visini said.
Earlier in May, Eli Lilly had also received permission for the emergency use of baricitinib in combination with remdesivir, for the treatment of suspected or laboratory confirmed Covid-19 in India, the statement said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU